Resected Pancreatic Cancer: Why Wait for the Inevitable?
Dr. John Marshall reports on a retrospective study suggesting that maintenance with capecitabine is a promising option in patients with resected pancreatic adenocarcinoma after adjuvant therapy.
Source: Medscape Gastroenterology Podcast - Category: Gastroenterology Authors: Medscape Source Type: podcasts
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastroenterology | Pancreas | Pancreatic Cancer | Podcasts | Study | Xeloda